Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)
Taiwan · Delayed Price · Currency is TWD 79.70
-0.20 (-0.25%)
At close: Dec 5, 2025
Foresee Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 519.61 | 418.69 | 195.04 | 301.51 | 226.03 | 230.44 | Upgrade | |
Revenue Growth (YoY) | 49.93% | 114.67% | -35.31% | 33.39% | -1.91% | 206.44% | Upgrade |
Cost of Revenue | 138.75 | 178.89 | 81.07 | 25.54 | 50.95 | 57.01 | Upgrade |
Gross Profit | 380.86 | 239.8 | 113.97 | 275.97 | 175.08 | 173.43 | Upgrade |
Selling, General & Admin | 166.21 | 147.32 | 160.16 | 124.23 | 99.07 | 120.58 | Upgrade |
Research & Development | 1,430 | 1,172 | 961.44 | 621.18 | 614.64 | 537.65 | Upgrade |
Operating Expenses | 1,597 | 1,320 | 1,122 | 745.41 | 713.71 | 658.23 | Upgrade |
Operating Income | -1,216 | -1,080 | -1,008 | -469.44 | -538.63 | -484.79 | Upgrade |
Interest Expense | -5.7 | -6.71 | -2.85 | -0.4 | -0.68 | -1 | Upgrade |
Interest & Investment Income | 19.14 | 28.28 | 23.53 | 8.34 | 3.53 | 1.04 | Upgrade |
Currency Exchange Gain (Loss) | 21.51 | 21.51 | -2.32 | 23.35 | -3.05 | 1.37 | Upgrade |
Other Non Operating Income (Expenses) | -26.56 | 3.26 | 0.83 | 1.2 | 10.17 | 0.1 | Upgrade |
EBT Excluding Unusual Items | -1,207 | -1,033 | -988.45 | -436.96 | -528.66 | -483.28 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 0.29 | 0.8 | 0.52 | Upgrade |
Gain (Loss) on Sale of Assets | -0.03 | -0.03 | -0.2 | -0.31 | -0.13 | -0.06 | Upgrade |
Asset Writedown | - | - | - | -1.16 | - | - | Upgrade |
Other Unusual Items | 0.28 | 0.28 | 0.01 | - | - | - | Upgrade |
Pretax Income | -1,207 | -1,033 | -988.64 | -438.13 | -527.99 | -482.81 | Upgrade |
Income Tax Expense | 18.55 | 47.87 | 47.67 | 34.51 | 41.28 | 27.9 | Upgrade |
Net Income | -1,226 | -1,081 | -1,036 | -472.64 | -569.27 | -510.71 | Upgrade |
Net Income to Common | -1,226 | -1,081 | -1,036 | -472.64 | -569.27 | -510.71 | Upgrade |
Shares Outstanding (Basic) | 151 | 137 | 127 | 118 | 117 | 101 | Upgrade |
Shares Outstanding (Diluted) | 151 | 137 | 127 | 118 | 117 | 101 | Upgrade |
Shares Change (YoY) | 10.81% | 7.89% | 7.82% | 0.57% | 15.74% | 5.71% | Upgrade |
EPS (Basic) | -8.13 | -7.87 | -8.14 | -4.00 | -4.85 | -5.04 | Upgrade |
EPS (Diluted) | -8.13 | -7.87 | -8.14 | -4.00 | -4.85 | -5.04 | Upgrade |
Free Cash Flow | -1,363 | -1,323 | -933.84 | -291.29 | -220.19 | -687.58 | Upgrade |
Free Cash Flow Per Share | -9.04 | -9.64 | -7.34 | -2.47 | -1.88 | -6.78 | Upgrade |
Gross Margin | 73.30% | 57.27% | 58.44% | 91.53% | 77.46% | 75.26% | Upgrade |
Operating Margin | -233.98% | -257.90% | -516.63% | -155.70% | -238.30% | -210.38% | Upgrade |
Profit Margin | -235.89% | -258.20% | -531.33% | -156.76% | -251.86% | -221.63% | Upgrade |
Free Cash Flow Margin | -262.35% | -316.07% | -478.80% | -96.61% | -97.42% | -298.38% | Upgrade |
EBITDA | -1,158 | -1,016 | -950.68 | -429.72 | -498.38 | -446.65 | Upgrade |
EBITDA Margin | -222.91% | -242.56% | - | -142.52% | -220.50% | -193.82% | Upgrade |
D&A For EBITDA | 57.51 | 64.2 | 56.95 | 39.72 | 40.24 | 38.14 | Upgrade |
EBIT | -1,216 | -1,080 | -1,008 | -469.44 | -538.63 | -484.79 | Upgrade |
EBIT Margin | -233.98% | -257.90% | - | -155.70% | -238.30% | -210.38% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.